[1] Wolinsky D, Drake K, Bostwick J.Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease[J].Curr Psychiatry Rep, 2018, 20(12):117. [2] Ballard C, Kales H C, Lyketsos C, et al.Psychosis in Alzheimer's disease[J].Curr Neurol Neurosci Rep, 2020, 20(12):57. [3] Tanaka H, Hashimoto M, Fukuhara R, et al.Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer's disease[J].Psychogeriatrics, 2015, 15(4):242-247. [4] Shimabukuro J, Awata S, Matsuoka H.Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients[J].Psychiatry Clin Neurosci, 2005, 59(3):274-279. [5] Scassellati C, Ciani M, Maj C, et al.Behavioral and Psychological Symptoms of Dementia (BPSD):Clinical Characterization and Genetic Correlates in an Italian Alzheimer's Disease Cohort[J].J Pers Med, 2020, 10(3):90. [6] Jack C R Jr, Bennett D A, Blennow K, et al.NIA-AA Research Framework:Toward a biological definition of Alzheimer's disease[J].Alzheimers Dement, 2018, 14(4):535-562. [7] Petersen R C, Wiste H J, Weigand S D, et al.NIA-AA Alzheimer's disease framework:clinical characterization of stages[J].Ann Neurol, 2021, 89(6):1145-1156. [8] Makimoto K, Kang Y, Kobayashi S, et al.Prevalence of behavioural and psychological symptoms of dementia in cognitively impaired elderly residents of long-term care facilities in East Asia:a cross-sectional study[J].Psychogeriatrics, 2019, 19(2):171-180. [9] Fernández-martinez M, Molano A, Castro J, et al.Prevalence of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease, and its relationship with cognitive impairment[J].Curr Alzheimer Res, 2010, 7(6):517-526. [10] Siafarikas N, Selbaek G, Fladby T, et al.Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease[J].Int Psychogeriatr, 2018, 30(1):103-113. [11] Tokuchi R, Hishikawa N, Sato K, et al.Age-dependent cognitive and affective differences in Alzheimer's and Parkinson's diseases in relation to MRI findings[J].J Neurol Sci, 2016, 365:3-8. [12] Carotenuto A, Rea R, Traini E, et al.The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in Alzheimer's disease:interim results of the ASCOMALVA Trial[J].J Alzheimers Dis, 2017, 56(2):805-815. [13] Bodick N C, Offen W W, Levey A I, et al.Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease[J].Arch Neurol, 1997, 54(4):465-473. [14] Udeh-Momoh C T, Su B, Evans S, et al.Cortisol, amyloid-β, and reserve predicts alzheimer's disease progression for cognitively normal older adults[J].J Alzheimers Dis, 2019, 70(2):553-562. [15] Zvěřová M, Fišar Z, Jirák R, et al.Plasma cortisol in Alzheimer's disease with or without depressive symptoms[J].Med Sci Monit, 2013, 19:681-689. [16] Tiemensma J, Andela C D, Kaptein A A, et al.Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency:cross-sectional study and review of the literature[J].Eur J Endocrinol, 2014, 171(2):171-182. [17] Chokroverty S.Sleep and neurodegenerative diseases[J].Semin Neurol, 2009, 29(4):446-467. [18] Granados-Fuentes D, Prolo L M, Abraham U, et al.The suprachiasmatic nucleus entrains, but does not sustain, circadian rhythmicity in the olfactory bulb[J].J Neurosci, 2004, 24(3):615-619. [19] Figueiro M G, Plitnick B, Roohan C, et al.Effects of a tailored lighting intervention on sleep quality, rest-activity, mood, and behavior in older adults with Alzheimer disease and related dementias:a randomized clinical trial[J].J Clin Sleep Med, 2019, 15(12):1757-1767. |